Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS
The results demonstrated Gilenya 0.5mg’s superior efficacy over glatiramer acetate 20mg in reducing the annualized relapse rate (ARR), a key measure of disease activity, with a 40.7% relative